Drug Profile
T 89
Alternative Names: Cardiotonic Pills; Compound Danshen Dripping Pills; Danshen Plus; Dantonic Capsule; Salvtonic; T89; Tasly Danshen Plus CapsuleLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Tianjin Tasly Pharmaceutical
- Developer Tasly Pharmaceutical Group; Tasly Pharmaceuticals, Inc.
- Class Anti-infectives; Eye disorder therapies; Herbal medicines; Ischaemic heart disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Angina pectoris
- Phase III Diabetic retinopathy; Respiration disorders
- No development reported COVID 2019 infections
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (PO, Capsule)
- 21 Jul 2021 Phase-III clinical trials in Respiration disorders (In volunteers) in USA (PO) (NCT04993729)
- 27 Nov 2020 Clinical trials in COVID-2019 infections (expanded access use) in USA (PO) (NCT04646031)